Product NDC: | 0378-2023 |
Proprietary Name: | Irbesartan |
Non Proprietary Name: | Irbesartan |
Active Ingredient(s): | 150 mg/1 & nbsp; Irbesartan |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0378-2023 |
Labeler Name: | Mylan Pharmaceuticals Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA200461 |
Marketing Category: | ANDA |
Start Marketing Date: | 20120928 |
Package NDC: | 0378-2023-77 |
Package Description: | 90 TABLET in 1 BOTTLE, PLASTIC (0378-2023-77) |
NDC Code | 0378-2023-77 |
Proprietary Name | Irbesartan |
Package Description | 90 TABLET in 1 BOTTLE, PLASTIC (0378-2023-77) |
Product NDC | 0378-2023 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Irbesartan |
Dosage Form Name | TABLET |
Route Name | ORAL |
Start Marketing Date | 20120928 |
Marketing Category Name | ANDA |
Labeler Name | Mylan Pharmaceuticals Inc. |
Substance Name | IRBESARTAN |
Strength Number | 150 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Angiotensin 2 Receptor Antagonists [MoA],Angiotensin 2 Receptor Blocker [EPC] |